Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 20 December 2021. Telix announces the FDA has approved Illuccix®, Telix’s lead prostate cancer imaging product. Telix is pleased to announce that the U.S. Food and Drug…Original Article
FDA Approves Illuccix (gallium Ga 68 gozetotide) for Prostate Cancer Imaging
